skip to content
Pharmacoeconomic review report. Nitisinone (Orfadin) (Sobi Canada Inc.). Preview this item
ClosePreview this item
Checking...

Pharmacoeconomic review report. Nitisinone (Orfadin) (Sobi Canada Inc.).

Author: Canadian Agency for Drugs and Technologies in Health,
Publisher: Ottawa (ON) : CADTH, April 2018.
Series: Common drug review clinical review report.
Edition/Format:   eBook : Document : English
Summary:
Nitisinone (Orfadin) is indicated for the treatment of patients with hereditary tyrosinemia type 1 (HT- 1) in combination with dietary restriction of tyrosine and phenylalanine. Nitisinone is available as 2 mg, 5 mg, 10 mg, and 20 mg capsules for oral administration. The submitted price of nitisinone is based on dose: 2 mg ($22.50), 5 mg ($53.30), 10 mg ($100), and 20 mg ($193.33). The recommended initial dosage in  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Canadian Agency for Drugs and Technologies in Health,
OCLC Number: 1084889178
Description: 1 online resource (1 PDF file (29 pages)) : illustrations.
Series Title: Common drug review clinical review report.
Other Titles: Nitisinone (Orfadin) (Sobi Canada Inc.)
CADTH common drug review pharmacoeconomic review report for nitisinone (Orfadin)

Abstract:

Nitisinone (Orfadin) is indicated for the treatment of patients with hereditary tyrosinemia type 1 (HT- 1) in combination with dietary restriction of tyrosine and phenylalanine. Nitisinone is available as 2 mg, 5 mg, 10 mg, and 20 mg capsules for oral administration. The submitted price of nitisinone is based on dose: 2 mg ($22.50), 5 mg ($53.30), 10 mg ($100), and 20 mg ($193.33). The recommended initial dosage in pediatric and adult populations is 1 mg/kg body weight daily divided in two doses administered orally. If plasma or urine succinylacetone is still detectable one month after starting treatment, the dosage should be increased to 1.5 mg/kg daily to a maximum dosage of 2 mg/kg daily. If the biochemical response is satisfactory, dosage should be adjusted only according to body weight gain. Although nitisinone can be used in both pediatric and adult populations, the manufacturer's economic evaluation is based on a subset of the labelled indication: the treatment of newborns who are identified and treated within one month of birth, either through a newborn screening program or through physical examination, patient history, and specialized tests (including urine succinylacetone levels). The submitted cost-utility analysis compares costs and health benefits associated with nitisinone 1 mg/kg plus best supportive care (BSC; dietary restriction) versus BSC (dietary restriction) alone in the treatment of newborns at least one month old, from a health ministry perspective. The model is based on three health states: diagnosed with HT-1; liver transplant with associated tunnel states; and dead. The time horizon was a patient's lifetime (100 years), and future costs and benefits were discounted at 1.5% annually. Comparative treatment effect was based on assumptions regarding premature mortality taken from a study of a Quebec-based cohort (Larochelle et al.) of newborns followed for up to 14 years. Utility values were derived from a cohort of men (average age 54 years) with decompensated cirrhosis resulting from chronic hepatitis B infection and measured with the Health Utility Index Mark 3 (HUI3) instrument. Assumptions regarding resource use and costs were derived from a Quebec-based study of HT-1 patients as well as a British Columbia-based study of liver transplantation costs.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/1084889178> # Pharmacoeconomic review report. Nitisinone (Orfadin) (Sobi Canada Inc.).
    a schema:Book, schema:MediaObject, schema:CreativeWork ;
    library:oclcnum "1084889178" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/8903043852#Place/canada> ; # Canada.
    schema:about <http://experiment.worldcat.org/entity/work/data/8903043852#Topic/cost_benefit_analysis> ; # Cost-Benefit Analysis
    schema:about <http://experiment.worldcat.org/entity/work/data/8903043852#Topic/tyrosinemias_diet_therapy> ; # Tyrosinemias--diet therapy
    schema:about <http://experiment.worldcat.org/entity/work/data/8903043852#Topic/nitrobenzoates_economics> ; # Nitrobenzoates--economics
    schema:about <http://experiment.worldcat.org/entity/work/data/8903043852#Topic/nitrobenzoates_therapeutic_use> ; # Nitrobenzoates--therapeutic use
    schema:about <http://experiment.worldcat.org/entity/work/data/8903043852#Topic/tyrosinemias_drug_therapy> ; # Tyrosinemias--drug therapy
    schema:about <http://experiment.worldcat.org/entity/work/data/8903043852#Topic/administration_oral> ; # Administration, Oral
    schema:alternateName "CADTH common drug review pharmacoeconomic review report for nitisinone (Orfadin)" ;
    schema:alternateName "Nitisinone (Orfadin) (Sobi Canada Inc.)" ;
    schema:bookFormat schema:EBook ;
    schema:contributor <http://experiment.worldcat.org/entity/work/data/8903043852#Organization/canadian_agency_for_drugs_and_technologies_in_health> ; # Canadian Agency for Drugs and Technologies in Health,
    schema:datePublished "2018" ;
    schema:description "Nitisinone (Orfadin) is indicated for the treatment of patients with hereditary tyrosinemia type 1 (HT- 1) in combination with dietary restriction of tyrosine and phenylalanine. Nitisinone is available as 2 mg, 5 mg, 10 mg, and 20 mg capsules for oral administration. The submitted price of nitisinone is based on dose: 2 mg ($22.50), 5 mg ($53.30), 10 mg ($100), and 20 mg ($193.33). The recommended initial dosage in pediatric and adult populations is 1 mg/kg body weight daily divided in two doses administered orally. If plasma or urine succinylacetone is still detectable one month after starting treatment, the dosage should be increased to 1.5 mg/kg daily to a maximum dosage of 2 mg/kg daily. If the biochemical response is satisfactory, dosage should be adjusted only according to body weight gain. Although nitisinone can be used in both pediatric and adult populations, the manufacturer's economic evaluation is based on a subset of the labelled indication: the treatment of newborns who are identified and treated within one month of birth, either through a newborn screening program or through physical examination, patient history, and specialized tests (including urine succinylacetone levels). The submitted cost-utility analysis compares costs and health benefits associated with nitisinone 1 mg/kg plus best supportive care (BSC; dietary restriction) versus BSC (dietary restriction) alone in the treatment of newborns at least one month old, from a health ministry perspective. The model is based on three health states: diagnosed with HT-1; liver transplant with associated tunnel states; and dead. The time horizon was a patient's lifetime (100 years), and future costs and benefits were discounted at 1.5% annually. Comparative treatment effect was based on assumptions regarding premature mortality taken from a study of a Quebec-based cohort (Larochelle et al.) of newborns followed for up to 14 years. Utility values were derived from a cohort of men (average age 54 years) with decompensated cirrhosis resulting from chronic hepatitis B infection and measured with the Health Utility Index Mark 3 (HUI3) instrument. Assumptions regarding resource use and costs were derived from a Quebec-based study of HT-1 patients as well as a British Columbia-based study of liver transplantation costs."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/8903043852> ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/8903043852#Series/common_drug_review_clinical_review_report> ; # Common drug review clinical review report.
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/8903043852#Series/cadth_common_drug_review> ; # CADTH common drug review
    schema:name "Pharmacoeconomic review report. Nitisinone (Orfadin) (Sobi Canada Inc.)."@en ;
    schema:productID "1084889178" ;
    schema:url <https://www.ncbi.nlm.nih.gov/books/NBK533442/> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/1084889178> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/8903043852#Organization/canadian_agency_for_drugs_and_technologies_in_health> # Canadian Agency for Drugs and Technologies in Health,
    a schema:Organization ;
    schema:name "Canadian Agency for Drugs and Technologies in Health," ;
    .

<http://experiment.worldcat.org/entity/work/data/8903043852#Series/cadth_common_drug_review> # CADTH common drug review
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1084889178> ; # Pharmacoeconomic review report. Nitisinone (Orfadin) (Sobi Canada Inc.).
    schema:name "CADTH common drug review" ;
    .

<http://experiment.worldcat.org/entity/work/data/8903043852#Series/common_drug_review_clinical_review_report> # Common drug review clinical review report.
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1084889178> ; # Pharmacoeconomic review report. Nitisinone (Orfadin) (Sobi Canada Inc.).
    schema:name "Common drug review clinical review report." ;
    .

<http://experiment.worldcat.org/entity/work/data/8903043852#Topic/administration_oral> # Administration, Oral
    a schema:Intangible ;
    schema:name "Administration, Oral"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8903043852#Topic/cost_benefit_analysis> # Cost-Benefit Analysis
    a schema:Intangible ;
    schema:name "Cost-Benefit Analysis"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8903043852#Topic/nitrobenzoates_economics> # Nitrobenzoates--economics
    a schema:Intangible ;
    schema:name "Nitrobenzoates--economics"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8903043852#Topic/nitrobenzoates_therapeutic_use> # Nitrobenzoates--therapeutic use
    a schema:Intangible ;
    schema:name "Nitrobenzoates--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8903043852#Topic/tyrosinemias_diet_therapy> # Tyrosinemias--diet therapy
    a schema:Intangible ;
    schema:name "Tyrosinemias--diet therapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8903043852#Topic/tyrosinemias_drug_therapy> # Tyrosinemias--drug therapy
    a schema:Intangible ;
    schema:name "Tyrosinemias--drug therapy"@en ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.